The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

Discover why refining COAs is essential to capturing subtle, meaningful patient change—and how teams can close the ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Collaborative discussions” with the FDA encouraged Praxis to submit early next year an approval filing for its epilepsy drug. Elsewhere, Rezolute shares plunged and Centessa announced a new CEO.

Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug ...

The legislation, which is scheduled for a vote Thursday, would send funds directly to health savings accounts paired with ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...